# US 2021/0171893 A1 · Lymphovascular invasion bioreactor and methods of making and using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171893 A1
- Document ID: US20210171893A1
- Status: Published application
- Kind: A1
- Application number: 16/762,857
- Filed: 2018-11-09
- Published: 2021-06-10
- Earliest claimed: 2017-11-09
- Assignees: Duke University
- Applicants: Duke University
- Inventors: David Brown; Gayathri Devi
- Web page: https://patentgrep.com/patent/US20210171893A1

## CPC

- C12M 35/08: {Chemical, biochemical or biological means, e.g. plasma jet, co-culture}
- C12M 23/14: {Bags}
- C12M 25/04: {in combination with well or multiwell plates, i.e. culture inserts}
- G01N 33/5017: {for testing neoplastic activity}
- G01N 33/57515: of the breast
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure comprises a lymphovascular bioreactor system and methods of making and using same.

## Claims

### Claim 1

An in vitro 3-D lymphovascular system comprising:
(a) a fluid chamber comprising medium in liquid communication with a transwell and a fluid pump,
(b) the transwell comprising a permeable membrane separating a basolateral surface and an apical compartment of the transwell, wherein the apical surface of the transwell comprises:
(i) lymphatic endothelial cells (LECs) seeded on the apical surface of the permeable membrane;
(ii) a layer of hydrogel above the seeded LECs layer, and
(iii) medium comprising tumor cells; and
(c) a fluid pump capable of creating steady-state flow rate of medium throughout the fluid chamber and transwell of the system.

### Claim 2 (depends on 1)

The lymphovascular system of claim 1, wherein the tumor cells are breast cancer cells.

### Claim 3 (depends on 1)

The lymphovascular system of claim 1, wherein the tumor cells are tumor emboli from inflammatory breast cancer.

### Claim 4 (depends on 1)

The lymphovascular system of claim 1, wherein the hydrogel of (ii) is collagen hydrogel.

### Claim 5 (depends on 1)

The lymphovascular system of claim 1, wherein the lymphatic endothelial cells and the tumor cells are from a patient having cancer.

### Claim 6 (depends on 5)

The lymphovascular system of claim 5, wherein the patient has breast cancer.

### Claim 7 (depends on 6)

The lymphovascular system of claim 6, wherein the patient has inflammatory breast cancer.

### Claim 8 (depends on 6)

The lymphovascular system of claim 6, wherein the patient has triple negative breast cancer.

### Claim 9 (depends on 1)

The lymphovascular system of claim 1, wherein the lymphatic endothelial cells provide a monolayer on the permeable membrane.

### Claim 10 (depends on 1)

The lymphovascular system of claim 1, wherein the permeable membrane has a pore diameter of about 5 μm to about 8 μm.

### Claim 11 (depends on 1)

The lymphovascular system of claim 1, wherein the layer of hydrogel is about 0.5 mm o about 2 mm thick.

### Claim 12 (depends on 1)

A method of testing the efficacy of an anti-cancer therapy, the method comprising contacting the 3-D lymphovascular system of claim 1 with the anti-cancer therapy; and measuring the efficacy of the therapy.

### Claim 13 (depends on 12)

The method of claim 12, wherein the efficacy of the therapy is measured by the ability of the anti-cancer drug to kill tumor cells in the 3-D lymphovascular system.

### Claim 14 (depends on 12)

The method of claim 12, wherein the anti-cancer therapy is an anti-cancer drug.

### Claim 15 (depends on 12)

The method of claim 12, wherein the anti-cancer therapy is a combination of two or more anti-cancer drugs.

### Claim 16 (depends on 5)

A method of screening for a patient-specific anticancer therapy, the method comprising: contacting a plurality of 3-D lymphovascular systems of claim 5 each with a different anticancer therapy, and assessing the efficacy of each anticancer therapy against the patient specific tumor cells in the system.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is breast cancer.

### Claim 18

A kit for producing a patient-specific 3-D lymphovascular system, the kit comprising: (a) a fluid chamber, (b) a transwell, (c) a fluid pump, (d) culture medium, and instructions for producing the patient-specific 3-D lymphovascular system.
